MOGAM is a private non-profit research foundation established to help people suffering from disease by contributing to the development of innovative medicines based on a scientific understanding of disease and therapeutics.
The story of the MOGAM began in 1984, founded on an endowment generated by the global success of Green Cross's Hepatitis B vaccine, the third of its kind developed in the world. Over the past four decades, we have been a cornerstone of Korea's biopharmaceutical advancement, systematically building the scientific knowledge, rigorous methodologies, and data-driven capabilities essential for drug discovery. In 2024, our 40th anniversary marked a pivotal milestone: a moment to build upon this profound heritage and redefine our purpose for the next era of medicine. Today, drug discovery is undergoing a monumental paradigm shift, driven by the powerful convergence of data and AI. Embracing this frontier, MOGAM accelerated its transformation into an AI-driven drug discovery institute in 2022. By placing computational power at our core, we are leveraging our advanced AI technologies to unprecedentedly enhance both the precision and speed of decision-making in the drug development process. Moving forward, MOGAM will continue to champion open innovation, serving as a vital nexus connecting academia and industry across the globe to advance AI-integrated therapeutics. Yet, at the heart of our cutting-edge technology remains a deeply human mission. Driven by a profound commitment to share the burden of even a single patient, we will be relentless in our fight against the diseases that threaten human health and well-being. Thank you.
